𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High activity 90Y-ibritumomab tiuxetan (Zevalin®) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas

✍ Scribed by Pier F. Ferrucci; Anna Vanazzi; Chiara M. Grana; Marta Cremonesi; Mirco Bartolomei; Marco Chinol; Mahila Ferrari; Davide Radice; Stefano Papi; Giovanni Martinelli; Giovanni Paganelli

Book ID
108675491
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
242 KB
Volume
139
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term responses in patients with rec
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w

Inducible lymphokine-activated killer (L
Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)
✍ Kenneth W. Zamkoff; Nora P. Watman; David B. Duggan; Bernard J. Poiesz; Arlan J. 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cell